Patent ID: 11913025
Assignee: CYTOARM CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of producing a tumor antigen-specific T cell from peripheral blood mononuclear cells (PBMCs) of a human subject, comprising:
culturing the PBMCs with a bi-specific antibody (BsAb) in a culture medium so as to produce the tumor antigen-specific T cell from the PBMCs,
wherein the BsAb comprises a tumor antigen binding site and a CD3 binding site, wherein
the tumor antigen binding site comprises an anti-tumor antigen scFv 100% identical to SEQ ID NO: 69; and
the CD3 binding site comprises an anti-CD3 VL-Ck domain 100% identical to SEQ ID NO: 67, and an anti-CD3 VH-CH1 domain 100% identical to SEQ ID NO: 68.